Skip to main content

Table 2 Influence of clinical parameters and gene mutations on OS

From: Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas

 

Univariate analysis a

Multivariate analysis b

HR

95%CI

P Value*

HR

95%CI

P Value*

Age ≥ 60

2.141

0.946–5.259

0.068

   

Gender

0.791

0.332–1.885

0.597

   

Pathological type

0.805

0.298–2.176

0.669

   

B symptom

1.114

0.498–2.493

0.792

   

Elevated LDH

2.703

1.079–6.772

0.034

   

ECOG > 1

0.040

0.000–7.141

0.224

   

Advanced stage

2.126

0.635–7.115

0.221

   

IPI score

0.944

0.396–2.251

0.897

   

Ki-67 > 75%

1.210

0.505–2.898

0.669

   

Extranodal involvement > 1

1.056

0.456–2.444

0.899

   

TET2 mutation

1.646

0.689–3.937

0.262

   

TP53 mutation

1.083

0.405–2.895

0.874

   

TET2/TP53 mutation

3.535

1.546–8.083

0.027

3.573

1.069–11.941

0.039

  1. OS Overall survival, HR Hazard ratio, CI Confidence interval, LDH Lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index
  2. aFactors with P < 0.10 in the univariate analyses were subjected to multivariate analysis afterwards, including age, elevated LDH, and TET2/TP53 mutation
  3. bForward stepwise Cox proportional-hazard modeling was used in multivariate analysis of risk factors
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us